PEDIATRIC CLINICAL TRIALS MARKET ANALYSIS

Pediatric Clinical Trials Market, By Phase (Phase I, Phase II, Phase III, and Phase IV), By Study Design (Treatment Studies and Observational Studies), By Therapeutic Area (Respiratory Diseases, Cardiovascular Diseases, and Neuropsychiatric Conditions, Oncology, Diabetes, and Others (Neuropsychiatric Conditions, etc.)), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Feb 2025
Code : CMI397
Pages :313
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenge - High termination rate of pediatric clinical trials due to various reasons

One major challenge in the pediatric clinical trials market is the high termination rate. Factors contributing to this include difficulties in patient enrollment due to a smaller target population, stringent safety standards, ethical concerns, and high dropout rates. Additionally, insufficient funding deters pharmaceutical companies from investing in pediatric research, while complex regulations and operational hurdles extend timelines and increase costs, prompting sponsors to abandon trials midway.

Market Opportunity - Increasing Partnerships and Collaborations

One of the major opportunities in the pediatric clinical trials market is the increasing partnerships and collaborations between various stakeholders. For instance, in February 2023, MMS Holdings Inc., a pharmaceutical company, announced a partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics including vaccines, medicines, and medical devices for children.